BRAF and cancer: Restoration of CST in patient-derived melanoma cells elicit marked cytotoxicity and apoptosis in lines with distinct molecular features—K06184 (wild-type BRAF, brain metastasis) and 156681 (BRAF^V600E, Vemurafenib-non-responder) and 128128 (treatment naïve, metastatic melanoma)—highlighting its broad anti-cancer efficacy across genotypes.